Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Eton Pharmaceuticals (ETON) over the last 6 years, with Dec 2024 value amounting to $14.9 million.

  • Eton Pharmaceuticals' Cash & Equivalents rose 83.21% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year increase of 83.21%. This contributed to the annual value of $14.9 million for FY2024, which is 30.17% down from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Cash & Equivalents of $14.9 million as of FY2024, which was down 30.17% from $21.4 million recorded in FY2023.
  • In the past 5 years, Eton Pharmaceuticals' Cash & Equivalents ranged from a high of $21.4 million in FY2023 and a low of $14.4 million during FY2021.
  • In the last 3 years, Eton Pharmaceuticals' Cash & Equivalents had a median value of $16.3 million in 2022 and averaged $17.5 million.
  • In the last 5 years, Eton Pharmaceuticals' Cash & Equivalents surged by 76.49% in 2020 and then plummeted by 32.35% in 2021.
  • Yearly analysis of 5 years shows Eton Pharmaceuticals' Cash & Equivalents stood at $21.3 million in 2020, then crashed by 32.35% to $14.4 million in 2021, then increased by 13.18% to $16.3 million in 2022, then surged by 31.17% to $21.4 million in 2023, then crashed by 30.17% to $14.9 million in 2024.